MEDANTA1,457.00

Global Health Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersMAXHEALTHAPOLLOHOSPFORTISGLAXOANTHEMAJANTPHARMIPCALABABBOTINDIAMcap ₹39,148 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations843.9832.6808.6861.1956.6943.4931.21,030.81,099.21,121.01,159.01,304.1
Other Income20.821.927.421.918.216.022.920.519.721.836.722.2
Total Income864.7854.5836.1883.0974.8959.5954.21,051.31,118.91,142.81,195.81,326.2
Expenses
+ Cost of Materials Consumed174.4172.2176.5187.6204.3206.6191.5213.1226.7226.7215.6257.2
+ Purchases of Stock-in-Trade20.018.117.623.128.220.720.531.828.828.927.840.7
+ Changes in Inventories-0.80.3-0.3-1.8-4.41.91.6-5.80.10.03.1-3.5
+ Employee Benefit Expense183.8184.9187.8201.2214.3205.0204.1256.4274.3280.7284.7319.3
+ Finance Costs20.117.718.218.016.016.315.013.817.121.526.726.7
+ Depreciation & Amortisation42.944.045.546.649.448.449.345.149.761.266.569.0
+ Other Expenses253.7245.0247.7264.7286.0271.5288.9308.4338.4367.4384.1403.7
Total Expenses694.1682.2693.0739.4793.7770.4770.8862.7935.1986.41,008.51,113.0
EBITDA212.9212.1179.3186.3228.3237.8224.7227.0230.9217.3243.8286.8
EBIT169.9168.1133.9139.7178.9189.3175.4181.9181.2156.1177.2217.8
Profit
PBT before Exceptional Items170.6172.4143.1143.7181.1189.1183.3188.5183.8156.4187.3213.3
+ Exceptional Items0.00.00.00.00.00.0-49.919.616.0-36.60.00.0
Pretax Income170.6172.4143.1143.7181.1189.1133.4208.1199.8119.8187.3213.3
+ Current Tax47.950.039.236.448.639.736.941.335.922.232.654.6
+ Deferred Tax-2.4-1.2-23.51.01.76.6-4.87.85.62.513.01.4
Tax Expense45.448.815.737.450.346.232.149.241.424.845.656.0
Net Income125.2123.5127.3106.3130.8142.9101.4159.0158.495.0141.7157.3
+ Net Income — Continuing Ops125.2123.5127.3106.3130.8142.9101.4159.0158.495.0141.7157.3
+ Other Comprehensive Income1.00.5-0.0-2.00.72.9-2.30.2-0.90.63.7-5.2
Total Comprehensive Income126.1124.1127.3104.2131.6145.799.1159.2157.595.7145.4152.1
Net Income to Common123.6127.4106.3142.9101.4159.0158.495.0144.0158.7
Minority Interest-0.1-0.0-0.0-0.0-0.0-0.0-0.00.0-2.3-1.5
Per Share
Basic EPS4.664.614.743.964.875.323.775.925.893.545.365.91
Diluted EPS4.664.604.743.964.875.323.775.915.893.545.345.90
Other Comprehensive Income — detail
+ Other Comprehensive Income-2.30.2-0.90.63.7-5.2
+ Items NOT to be Reclassified to P&L1.20.7-0.0-2.71.03.8-3.0-1.20.8
+ Tax on Items NOT to be Reclassified-0.8-0.3-0.30.2-5.26.9
+ Tax on Items NOT to be Reclassified — alt tag0.20.20.0-0.70.31.0
+ Items to be Reclassified to P&L-0.2
+ Tax on Items to be Reclassified0.11.3-1.7
Comprehensive Income — Owners of Parent126.1124.2127.4104.3131.6145.8-2.30.2-0.90.63.7-5.2
Comprehensive Income — Non-controlling Interests0.0-0.1-0.0-0.0-0.0-0.00.00.00.00.00.0-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations4.664.614.743.964.875.323.775.925.893.545.365.91
Diluted EPS — Continuing Operations4.664.604.743.964.875.323.775.915.893.545.345.90
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit650.4641.9614.9652.2728.6714.2717.6791.8843.7865.4912.51,009.7
Gross Margin %77.0677.1076.0475.7476.1775.7177.0676.8176.7577.1978.7377.43
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)170.6172.4143.1143.7181.1189.1183.3188.5183.8156.4187.3213.3
− Exceptional Items (reconciliation)0.00.00.00.00.00.0-49.919.616.0-36.60.00.0
Net Income Adj (tax-effected)125.2123.5127.3106.3130.8142.9139.3144.0145.7124.1141.7157.3
EPS Adj4.664.614.743.964.875.325.185.365.424.625.365.91
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital53.753.753.753.753.753.753.753.853.853.853.753.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.